1990年～2000年の論文
【論文タイトル /// 全著者名 /// 掲載誌】
Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia: /// R.Ohno, M.Tomonaga, T.Kobayashi, A.Kanamura, S.Shirakawa, T.Masaoka, M.Omine, H.Oh, T.Nomura, Y.Nakayama, Y.Yoshida, A.B.Miura, Y.Morishima, H.Dohy, Y.Niho, N.Hamajima and F.Takaku. /// N Eng J Med 323:871-877,1990
Randomized study of individualized induction therapy with or without VCR, and of maintenance 4 or 12 courses in adult AML: JALSG-AML87. /// R.Ohno, T.Kobayashi, Y.Morishima, A.Hiraoka, N.Naoe and Japan Adult Leukemia Study Group (JALSG). /// Leukemia 6(Supplement 2):92-95,1992
No increase of leukemia relapse in newly diagnosed patients with acute myeloidleukemia who received granulocyte colony-stimulating factor for life-threatening infection during remission induction and consolidation therapy. /// R.Ohno, A.Hiraoka, M.Tanimoto, N.Asou, K.Kuriyama, T.Kobayashi, H.Teshima, H.Saito, K.Fujimoto and Japan Adult Leukemia Study Group (JALSG). /// Blood 81:561-562,1993
Treatment of myelodysplastic syndromes with all-trans retinoic acid. /// R.Ohno, T.Naoe, M.Hirano, M.Kobayashi, H.Hirai, K.Tubaki, H.Oh and the Leukemia Study Group of Ministry of Heath and Welfare. /// Blood 81:1152-1154,1993
Current progress in the treatment of adult acute leukemia in Japan. /// R.Ohno. /// Japanese Journal of Clinical Oncology 22:85-97,1993
Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 study of the Japan Adult Leukemia Study Group. /// R.Ohno, T.Kobayashi, M.Tanimoto, A.Hiraoka, K.Imai, N.Asou, M.Tomonaga, K.Tsubaki, I.Takahashi, Y.Kodera, M.Yoshida, H.Murakami, T.Naoe, M.Shimoyama, T.Tukada, T.Takeo, H.Teshima, Y.Onozawa, K.Fujimoto, K.Kuriyama, A.Horiuchi, I.Kimura, S.Minami, Y.Miura, S.Kageyama, T.Tahara, T.Masaoka, S.Shirakawa and H.Saito. /// Cancer 71:3888-3895,1993
Multi-institutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. /// R.Ohno, H.Yoshida, H.Fukutani, T.Naoe, T.Ohshima, T.Kyo, N.Endoh, T.Fujimoto, T.Kobayashi, A.Hiraoka, H.Mizoguchi, Y.Kodera, H.Suzuki, M.Hirano, H.Akiyama, N.Aoki, H.Shindo, S.Yokomaku and the Leukemia Study Group of the Ministry of Health and Welfare. /// Leukemia 7:1722-1727,1993
Randomized study of intensive individualized induction therapy with or without vincristine and of maintenance/intensification therapy in adult acute myeloid leukemia. /// R.Ohno, T.Kobayashi, M.Tanimoto, A.Hiraoka, K.Imai, K.Fujimoto, M.Tomonaga, K.Tsubaki, E.Ohmoto, Y.Kodera, H.Murakami, M.Yoshida and Japan Adult Leukmemia Study Group (JALSG). /// Acute Leukemias:645-649,1993
Treatment of acute promyelocytic leukemia with all-trans retinoic acid and molecular analysis of the t(15;17) translocation. /// T.Naoe, H.Fukutani, H.Yoshida, S.Yamamori, R.Ohno and Kouseishou APL Study Group. /// Cancer Chemotherapy 8:166-171,1993
A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. /// R.Ohno, M.Tomonaga, T.Ohshima, T.Masaoka, N.Asou, H.Oh, K.Nishikawa, A.Kanamaru, H.Murakami, S.Furusawa, M.Hirano, K.Tsubaki, K.Imai, T.Ueda, Y.Kuraishi, N.Ogawa, Japan Adult Leukemia Study Group (JALSG). /// Inter J Hematol 58:73-81,1993
Japanese B cell chronic Lymphocytic leukemia:a cytogenetic and molecular biological study. /// H.Asou, M.Takechi, K.Tanaka, S.Tashiro, H.Dohy, R.Ohno and N.Kamada. /// Br J Haematol 85:492-497,1993
Treatment of myelodysplastic syndromes with all-trans retinoic acid. /// R.Ohno, T.Naoe, M.Hirano, M.Kobayashi, H.Hirai, K.Tubaki, H.Oh and the Leukemia Study Group of Ministry of Heath and Welfare. /// Blood 81:1152-1154,1993
Current progress in the treatment of adult acute leukemia in Japan. /// R.Ohno. /// Japanese Journal of Clinical Oncology 22:85-97,1993
Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 study of the Japan Adult Leukemia Study Group. /// R.Ohno, T.Kobayashi, M.Tanimoto, A.Hiraoka, K.Imai, N.Asou, M.Tomonaga, K.Tsubaki, I.Takahashi, Y.Kodera, M.Yoshida, H.Murakami, T.Naoe, M.Shimoyama, T.Tukada, T.Takeo, H.Teshima, Y.Onozawa, K.Fujimoto, K.Kuriyama, A.Horiuchi, I.Kimura, S.Minami, Y.Miura, S.Kageyama, T.Tahara, T.Masaoka, S.Shirakawa and H.Saito. /// Cancer 71:3888-3895,1993
Multi-institutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. /// R.Ohno, H.Yoshida, H.Fukutani, T.Naoe, T.Ohshima, T.Kyo, N.Endoh, T.Fujimoto, T.Kobayashi, A.Hiraoka, H.Mizoguchi, Y.Kodera, H.Suzuki, M.Hirano, H.Akiyama, N.Aoki, H.Shindo, S.Yokomaku and the Leukemia Study Group of the Ministry of Health and Welfare. /// Leukemia 7:1722-1727,1993
Randomized study of intensive individualized induction therapy with or without vincristine and of maintenance/intensification therapy in adult acute myeloid leukemia. /// R.Ohno, T.Kobayashi, M.Tanimoto, A.Hiraoka, K.Imai, K.Fujimoto, M.Tomonaga, K.Tsubaki, E.Ohmoto, Y.Kodera, H.Murakami, M.Yoshida and Japan Adult Leukmemia Study Group (JALSG). /// Acute Leukemias:645-649,1993
Treatment of acute promyelocytic leukemia with all-trans retinoic acid and molecular analysis of the t(15;17) translocation. /// T.Naoe, H.Fukutani, H.Yoshida, S.Yamamori, R.Ohno and Kouseishou APL Study Group. /// Cancer Chemotherapy 8:166-171,1993
A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. /// R.Ohno, M.Tomonaga, T.Ohshima, T.Masaoka, N.Asou, H.Oh, K.Nishikawa, A.Kanamaru, H.Murakami, S.Furusawa, M.Hirano, K.Tsubaki, K.Imai, T.Ueda, Y.Kuraishi, N.Ogawa, Japan Adult Leukemia Study Group (JALSG). /// Inter J Hematol 58:73-81,1993
Japanese B cell chronic Lymphocytic leukemia:a cytogenetic and molecular biological study. /// H.Asou, M.Takechi, K.Tanaka, S.Tashiro, H.Dohy, R.Ohno and N.Kamada. /// Br J Haematol 85:492-497,1993
Poor response to intensive chemotherapy in de novo acute myeloid leukaemia with trilineage mylodysplasia. /// K.Kuriyama, M.Tomonaga, T.Matsuo, T.Kobayashi, H.Miwa, S.Shirakawa, M.Tanimoto, K.Adachi, N.Emi, A.Hiraoka, N.Tominaga, K.Imai, N.Asou, K.Tsubaki, I.Takahashi, S.Minami, M.Yoshida, H.Murakami, K.Minato, T.Ohshima, S.Furusawa, R.Ohno and the Japan Adult Leukemia Study Group (JALSG). /// Br J Haematol 86:767-773,1994
A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. /// R.Ohno, T.Naoe, A.Kanamaru, M.Yoshida, A.Hiraoka, T.Kobayashi, T.Ueda, S.Minami, Y.Morishima, Y.Saito, S.Furusawa, K.Imai, Y.Takemoto, Y.Miura, H.Teshima, N.Hamajima and the Kohseisho Leukemia Study Group. /// Blood 83:2086-2092,1994
Differentiation therapy of myelodysplastic syndromes with retinoic acid. /// R.Ohno. /// Leukemia & Lymphoma 14:401-409,1994
All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia(APL) in Japan. /// R.Ohno, K.Ohnishi, A.Takeshita, M.Tanimoto, H.Murakami, A.Kanamaru, N.Asou, T.Kobayashi, K.Kuriyama, E.Ohmoto, H.Sakamaki, K.Tsubaki, A.Hiraoka, O.Yamada, H.Oh, S.Furusawa, S.Matsuda and T.Naoe. /// Leukemia 8(suppl.3):S64-S69,1994
G-CSF in the treatment of acute myeloid leukemia:is it safe? /// R.Ohno. /// Leukemia and Lymphoma 11(Suppl.2):15-19,1994
A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. /// R.Ohno, T.Naoe, A.Kanamaru, M.Yoshida, A.Hiraoka, T.Kobayashi, T.Ueda, S.Minami, Y.Morishima, Y.Saito, S.Furusawa, K.Imai, Y.Takemoto, Y.Miura, H.Teshima, N.Hamajima and the Kohseisho Leukemia Study Group. /// Blood 83:2086-2092,1994
Differentiation therapy of myelodysplastic syndromes with retinoic acid. /// R.Ohno. /// Leukemia & Lymphoma 14:401-409,1994
All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia(APL) in Japan. /// R.Ohno, K.Ohnishi, A.Takeshita, M.Tanimoto, H.Murakami, A.Kanamaru, N.Asou, T.Kobayashi, K.Kuriyama, E.Ohmoto, H.Sakamaki, K.Tsubaki, A.Hiraoka, O.Yamada, H.Oh, S.Furusawa, S.Matsuda and T.Naoe. /// Leukemia 8(suppl.3):S64-S69,1994
G-CSF in the treatment of acute myeloid leukemia:is it safe? /// R.Ohno. /// Leukemia and Lymphoma 11(Suppl.2):15-19,1994
All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. /// A.Kanamaru, Y.Takemoto, M.Tanimoto, H.Murakami, N.Asou, T.Kobayashi, K.Kuriyama, E.Ohmoto, H.Sakamaki, K.Tsubaki, A.Hiraoka, O.Yamada, H.Oh, K.Saito, S.Matsuda, K.Minato, T.Ueda, R.Ohno and the Japan Adult Leukemia Study Group (JALSG). /// Blood 85:1202-1206,1995
Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia. /// H.Fukutani, T.Naoe, R.Ohno , H.Yoshida, H.Kiyoi, S.Miyawaki, H.Morishita, F.Sano, H.Kamibayashi, K.Matsue, T.Miyake, S.Hasegawa, Y.Ueda, T.Kato, H.Kobayashi, C.Shimazaki, M.Kobayashi, R.Kurane, H.Sakota, K.Masaki, T.Wakayama, K.Tohyama, Y.Nonaka, H.Natori and the leukemia Study Group of the Ministry of Health and Welfare (Kouseisho). /// Leukemia9:588-593,1995
All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia [letter; comment]. /// A.Kanamaru and R.Ohno. /// Blood 86:1644-1645,1995
A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. /// K.Ohnishi, R.Ohno, M.Tomonaga, N.Kamada, K.Onozawa, A.Kuramoto, H.Dohy, H.Mizoguchi, S.Miyawaki, K.Tsubaki, Y.Miura, M.Omine, T.Kobayashi, T.Naoe, T.Ohshima, K.Hirashima, S.Ohtake, I,Takahashi, Y.Morishima, K.Naito, N.Asou, M.Tanimoto, A.Sakuma, K.Yamada and the Kouseisho Lukemia Study Group. /// Blood 86:906-916,1995
Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. /// H.Fukutani, T.Naoe, R.Ohno, H.Yoshida, S.Miyawaki, C.Simazaki, T.Miyake, Y.Nakayama, H.Kobayashi, S.Goto, A.Takeshita, S.Kobayashi, Y.Kato, K.Shiraishi, M.Sasada, S.Ohtake, H.Murakami, M.Kobayashi, N.Endo, H.Shindo, K.Matsushita, S.Hasegawa, K.Tsuji, Y.Ueda, N.Tominaga, H.Furuya, Y.Inoue, J.Takeuchi, H.Morishita, H.Iida, and the Leukemia Study Group of the Ministry of Health and Welfare(Kohseisho). /// Leukemia9:1478-1482,1995
Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. /// A.Takeshita, H.Sakamaki, S.Miyawaki, T.Kobayashi, K.Kuriyama, O.Yamada, H.Oh, T.Takenaka, N.Asou, R.Ohno and the Japan Adult Leukemia Sutdy Group (JALSG). /// Cancer76:602-608,1995
Recent progress in the treatment of adult acute leukemia in Japan. /// R.Ohno for the Japan Adalt Leukemia Study Group (JALSG). /// Cancer Chemotherapy 10:73-79,1995
Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia. /// H.Fukutani, T.Naoe, R.Ohno , H.Yoshida, H.Kiyoi, S.Miyawaki, H.Morishita, F.Sano, H.Kamibayashi, K.Matsue, T.Miyake, S.Hasegawa, Y.Ueda, T.Kato, H.Kobayashi, C.Shimazaki, M.Kobayashi, R.Kurane, H.Sakota, K.Masaki, T.Wakayama, K.Tohyama, Y.Nonaka, H.Natori and the leukemia Study Group of the Ministry of Health and Welfare (Kouseisho). /// Leukemia9:588-593,1995
All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia [letter; comment]. /// A.Kanamaru and R.Ohno. /// Blood 86:1644-1645,1995
A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. /// K.Ohnishi, R.Ohno, M.Tomonaga, N.Kamada, K.Onozawa, A.Kuramoto, H.Dohy, H.Mizoguchi, S.Miyawaki, K.Tsubaki, Y.Miura, M.Omine, T.Kobayashi, T.Naoe, T.Ohshima, K.Hirashima, S.Ohtake, I,Takahashi, Y.Morishima, K.Naito, N.Asou, M.Tanimoto, A.Sakuma, K.Yamada and the Kouseisho Lukemia Study Group. /// Blood 86:906-916,1995
Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. /// H.Fukutani, T.Naoe, R.Ohno, H.Yoshida, S.Miyawaki, C.Simazaki, T.Miyake, Y.Nakayama, H.Kobayashi, S.Goto, A.Takeshita, S.Kobayashi, Y.Kato, K.Shiraishi, M.Sasada, S.Ohtake, H.Murakami, M.Kobayashi, N.Endo, H.Shindo, K.Matsushita, S.Hasegawa, K.Tsuji, Y.Ueda, N.Tominaga, H.Furuya, Y.Inoue, J.Takeuchi, H.Morishita, H.Iida, and the Leukemia Study Group of the Ministry of Health and Welfare(Kohseisho). /// Leukemia9:1478-1482,1995
Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. /// A.Takeshita, H.Sakamaki, S.Miyawaki, T.Kobayashi, K.Kuriyama, O.Yamada, H.Oh, T.Takenaka, N.Asou, R.Ohno and the Japan Adult Leukemia Sutdy Group (JALSG). /// Cancer76:602-608,1995
Recent progress in the treatment of adult acute leukemia in Japan. /// R.Ohno for the Japan Adalt Leukemia Study Group (JALSG). /// Cancer Chemotherapy 10:73-79,1995
Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. /// T.Kobayashi, S.Miyawaki, M.Tanimoto, K.Kuriyama, H.Murakami, M.Yoshida, S.Minami, K.Tsubaki, E.Ohmoto, H.Oh, I.Jinnai, H.Sakamaki, A.Hiraoka, A.Kanamaru, I.Takahashi, K.Saito, T.Naoe, O.Yamada, N.Asou, S.Kageyama, N.Emi, A.Matsuoka, M.Tomonaga, H.Saito, R.Ueda, and R.Ohno for the Japan Adult Leukemia Study Group(JALSG). /// Journal of Clinical Oncology 14:204-213,1996
Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, Am80. /// A.Takeshita, Y.Shibata, K.Shinjo, M.Yanagi, T.Tobita, K.Ohnishi, S.Miyawaki, K.Shudo and R.Ohno. /// Annals of Internal Medicine 124:893-896,1996
Expression of costimulatory molecules in human leukemias. /// N.Hirano, T.Takahashi, T.Takahashi, S.Ohtake, K.Hirashima, N.Emi, K.Saito, M.Hirano, K.Shinohara, M.Takeuchi, F.Taketazu, S.Tsunoda, M.Ogura, M.Omine, T.Sito, Y.Yazaki, R.Ueda, H.Hirai. /// Leukemia10:1168-1176,1996
Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p161NK4A CDKN2, MTS2/p151NK4B, p53, and Rb genes in primary lymphoid malignancies. /// A.Hangaishi, S.Ogawa, N.Imamura, S.Miyawaki, Y.Miura, N.Uike, C.Shimazaki, N.Emi, K.Takeyama, S.Hirosawa, N.Kamada, Y.Kobayashi, Y.Takemoto, T.Kitani, K.Toyama, S.Ohtake, Y.Yazaki, R.Ueda, H.Hirai. /// Blood 87:4949-4958,1996
Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, Am80. /// A.Takeshita, Y.Shibata, K.Shinjo, M.Yanagi, T.Tobita, K.Ohnishi, S.Miyawaki, K.Shudo and R.Ohno. /// Annals of Internal Medicine 124:893-896,1996
Expression of costimulatory molecules in human leukemias. /// N.Hirano, T.Takahashi, T.Takahashi, S.Ohtake, K.Hirashima, N.Emi, K.Saito, M.Hirano, K.Shinohara, M.Takeuchi, F.Taketazu, S.Tsunoda, M.Ogura, M.Omine, T.Sito, Y.Yazaki, R.Ueda, H.Hirai. /// Leukemia10:1168-1176,1996
Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p161NK4A CDKN2, MTS2/p151NK4B, p53, and Rb genes in primary lymphoid malignancies. /// A.Hangaishi, S.Ogawa, N.Imamura, S.Miyawaki, Y.Miura, N.Uike, C.Shimazaki, N.Emi, K.Takeyama, S.Hirosawa, N.Kamada, Y.Kobayashi, Y.Takemoto, T.Kitani, K.Toyama, S.Ohtake, Y.Yazaki, R.Ueda, H.Hirai. /// Blood 87:4949-4958,1996
Application of fluorescence in situ hybridization to detect residual leukemic cells with 9;22 and 15;17 translocations. /// K.Tanaka, M.Arif, M.Eguchi, T.S.Kumaravel, R.Ueda, R.Ohno, K.Iwato, T.Kyo, H.Dohy and N.Kamada. /// Leukemia11:436-440,1997
Case-control study of leukemia and diagnostic radiation exposure. /// H.Yuasa, N.Hamajima, R.Ueda, R.Ohno, N.Asou, A.Utsunomiya, M.Ogura, N.Takigawa, T.Ueda, A.Hiraoka, S.Matsuda, Y.Kuraishi, K.Nishikawa, N.Uike, A.Takeshita, Y.Takemoto, C.Shimazaki, H.Sakamaki, T.Ino, T.Matsushima, K.Kuriyama, H.Hirai, T.Naoe, K.Tsubaki, M.Takahashi, K.Takeyama, Y.Morishima, K.Itoh. /// Inter J Haematol 65:251-261,1997
Morpholosgical subtyping of acute myeloid leukemia with maturation (AML-M2): homogeneous pink-coloared cytoplasm of mature neutrophils is most characteristic of AML-M2 with t(8;21). /// H.Nakamura, K.Kuriyama, N.Sadamori, M.Mine, T.Itoyama, I.Sasagawa, K.Matsumoto, Y.Tsuji, N.Asou, S.I.Kageyama, H.Sakamaki, N.Emi, R.Ohno and M.Tomonaga. /// Leukemia11:651-655,1997
Treatment with a new synthetic retinoid, Am80,of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. /// T.Tobita, A.Takeshita, K.Kitamura, K.Ohnishi, M.Yanagi, A.Hiraoka, T.Karasuno, M.Takeuchi, S.Miyawaki, R.Ueda, T.Naoe and R.Ohno. /// Blood90(3):967-973,1997
Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia:a double-blind controlled study. /// R.Ohno, S.Miyawaki, K.Hatake, K.Kuriyama, K.Saito, A.Kanamaru, T.Kobayashi, Y.Kodera, K.Nishikawa, S.Matsuda, O.Yamada, E.Omoto, H.Takeyama, K.Tsukuda, N.Asou, M.Tanimoto, H.Shiozaki, M.Tomonaga, T.Masaoka, Y.Miura, F.Takaku, Y.Ohashi and K.Motoyoshi. /// Journal of Clinical Oncology 15(8):2954-2965,1997
All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. /// N.Asou, K.Adachi, J.Tamura, A.Kanamaru, S.Kageyama, A.Hiraoka, E.Omoto, H.Sakamaki, K.Tsubaki, K.Saito, R.Ohno and the Japan Adult Leukemia Study Group (JALSG). /// Cancer Chemother Pharmacol 40:S30-S35,1997
Internal trandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. /// H.Kiyoi, T.Naoe, S.Yokota, M.Nakao, S.Minami, K.Kuriyama, A.Takeshita, K.Saito, S.Hasegawa, S.Shimodaira, J.tamura, C.Shimazaki, K.Matsue, H.Kobayashi, N.Arima, R.Suzuki, H.Morishita, H.Saito, R.Ueda, R.Ohno and the Leukemia Study Group of the Ministry of Health and Welfare(Kohseisho). /// Leukemia 11:1447-1452,1997
Case-control study of leukemia and diagnostic radiation exposure. /// H.Yuasa, N.Hamajima, R.Ueda, R.Ohno, N.Asou, A.Utsunomiya, M.Ogura, N.Takigawa, T.Ueda, A.Hiraoka, S.Matsuda, Y.Kuraishi, K.Nishikawa, N.Uike, A.Takeshita, Y.Takemoto, C.Shimazaki, H.Sakamaki, T.Ino, T.Matsushima, K.Kuriyama, H.Hirai, T.Naoe, K.Tsubaki, M.Takahashi, K.Takeyama, Y.Morishima, K.Itoh. /// Inter J Haematol 65:251-261,1997
Morpholosgical subtyping of acute myeloid leukemia with maturation (AML-M2): homogeneous pink-coloared cytoplasm of mature neutrophils is most characteristic of AML-M2 with t(8;21). /// H.Nakamura, K.Kuriyama, N.Sadamori, M.Mine, T.Itoyama, I.Sasagawa, K.Matsumoto, Y.Tsuji, N.Asou, S.I.Kageyama, H.Sakamaki, N.Emi, R.Ohno and M.Tomonaga. /// Leukemia11:651-655,1997
Treatment with a new synthetic retinoid, Am80,of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. /// T.Tobita, A.Takeshita, K.Kitamura, K.Ohnishi, M.Yanagi, A.Hiraoka, T.Karasuno, M.Takeuchi, S.Miyawaki, R.Ueda, T.Naoe and R.Ohno. /// Blood90(3):967-973,1997
Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia:a double-blind controlled study. /// R.Ohno, S.Miyawaki, K.Hatake, K.Kuriyama, K.Saito, A.Kanamaru, T.Kobayashi, Y.Kodera, K.Nishikawa, S.Matsuda, O.Yamada, E.Omoto, H.Takeyama, K.Tsukuda, N.Asou, M.Tanimoto, H.Shiozaki, M.Tomonaga, T.Masaoka, Y.Miura, F.Takaku, Y.Ohashi and K.Motoyoshi. /// Journal of Clinical Oncology 15(8):2954-2965,1997
All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. /// N.Asou, K.Adachi, J.Tamura, A.Kanamaru, S.Kageyama, A.Hiraoka, E.Omoto, H.Sakamaki, K.Tsubaki, K.Saito, R.Ohno and the Japan Adult Leukemia Study Group (JALSG). /// Cancer Chemother Pharmacol 40:S30-S35,1997
Internal trandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. /// H.Kiyoi, T.Naoe, S.Yokota, M.Nakao, S.Minami, K.Kuriyama, A.Takeshita, K.Saito, S.Hasegawa, S.Shimodaira, J.tamura, C.Shimazaki, K.Matsue, H.Kobayashi, N.Arima, R.Suzuki, H.Morishita, H.Saito, R.Ueda, R.Ohno and the Leukemia Study Group of the Ministry of Health and Welfare(Kohseisho). /// Leukemia 11:1447-1452,1997
Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. /// N.Asou, K.Adachi, J.Tamura, A.Kanamaru, S.Kageyama, A.Hiraoka, E.Omoto, H.Akiyama, K.Tsubaki, K.Saito, K.Kuriyama, H.Oh, K.Kitano, S.Miyawaki, K.Takeyama, O.Yamada, K.Nishikawa, M.Takahashi, S.Matsuda, S.Ohtake, H.Suzushima, N.Emi, R.Ohno and the Japan Adult Leukemia Study Group (JALSG). /// Journal of Clinical Oncology 16(1):78-85,1998
Chemotherapy vs HLA-indentical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. /// H.Oh, RP Gale, M-J Zhang, JR Passweg, T Ino, H Murakami, R Ohno, PA Rowlings, KA Sobocinski, M Tanimoto, M Tomonaga, DJ Weisdorf and MM Horowitz. /// Bone Marrow Transplant. 22:253-257,1998
Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group. /// T.Ueda, S.Miyawaki, N.Asou, Y.Kuraishi, A.Hiraoka, K.Kuriyama, S.Minami, T.Ohsima, T.Ino, J.Tamura, A.Kanamaru, K.Nishikawa, M.Tanimoto, H.OH, K.saito, K.Nagata, T.Naoe, O.Yamada, Y.Urasaki, T.Sakura, R.Ohno. /// Inter J Hematol 68:279-289,1998
Response-oriented individualized indeuction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: Thed ALL-87 Study of the Japan Adult Leukemia Study Group. /// M.tanimoto, S.Miyawaki, T.Ino, T.Kyo, H.Sakamaki, T.Naoe, A.Hiraoka, N.Asou, T.Ohshima, K.Tsubaki, K.Kuriyama, T.Ueda, S.MInami, K.Okabe,H.Saito, H.Murakami, M.Hirano, H.Dohy, Y.Onozawa, H.Suzuki, R.Ohno. /// Inter J Hematol 68:421-429,1998
Cooperative oncology groups in Japan: experience from the Japan Adult Leukemia Study Group. /// Ohno R. /// Cancer Chemother Pharmacol42 Suppl:S93-97,1998
Multicenter cooperative study group in hematology in Japan: the 10-year history and role of the Japan Adult Leukemia Study Group in Japan. /// Ohno R. /// Int J Hematol67(3):213-219,1998
Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. /// R.Ohno. /// Leuk Res 22(12):1143-1154,1998
Chemotherapy vs HLA-indentical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. /// H.Oh, RP Gale, M-J Zhang, JR Passweg, T Ino, H Murakami, R Ohno, PA Rowlings, KA Sobocinski, M Tanimoto, M Tomonaga, DJ Weisdorf and MM Horowitz. /// Bone Marrow Transplant. 22:253-257,1998
Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group. /// T.Ueda, S.Miyawaki, N.Asou, Y.Kuraishi, A.Hiraoka, K.Kuriyama, S.Minami, T.Ohsima, T.Ino, J.Tamura, A.Kanamaru, K.Nishikawa, M.Tanimoto, H.OH, K.saito, K.Nagata, T.Naoe, O.Yamada, Y.Urasaki, T.Sakura, R.Ohno. /// Inter J Hematol 68:279-289,1998
Response-oriented individualized indeuction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: Thed ALL-87 Study of the Japan Adult Leukemia Study Group. /// M.tanimoto, S.Miyawaki, T.Ino, T.Kyo, H.Sakamaki, T.Naoe, A.Hiraoka, N.Asou, T.Ohshima, K.Tsubaki, K.Kuriyama, T.Ueda, S.MInami, K.Okabe,H.Saito, H.Murakami, M.Hirano, H.Dohy, Y.Onozawa, H.Suzuki, R.Ohno. /// Inter J Hematol 68:421-429,1998
Cooperative oncology groups in Japan: experience from the Japan Adult Leukemia Study Group. /// Ohno R. /// Cancer Chemother Pharmacol42 Suppl:S93-97,1998
Multicenter cooperative study group in hematology in Japan: the 10-year history and role of the Japan Adult Leukemia Study Group in Japan. /// Ohno R. /// Int J Hematol67(3):213-219,1998
Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. /// R.Ohno. /// Leuk Res 22(12):1143-1154,1998
Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. /// S.Miyawaki, T.Kobayashi, M.Tanimoto, K.Kuriyama, H.Murakami, M.Yoshida, S.Minami, K.Minato, K.Tsubaki, E.Omoto, H.Oh, I.Jinnai, H.Sakamaki, A.Hiraoka, A.Kanamaru, I.Takahashi, K.Saito, T.Naoe, O.Yamada, N.Asou, S.Kageyama, N.Emi, T.Ueda, M.Tomonaga, H.Saito, R.Ueda, R.Ohno, for the Japan Adult Leukemia Study Group. /// Inter J Hematol 70:56-57,1999
No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6- mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. /// S.Miyawaki, M.Tanimoto, T.Kobayashi, S.Minami, J.Tamura, E.Omoto, K.Kuriyama, K.Hatake, K.Saito, A.Kanamaru, H.Oh, S.Ohtake, N.Asou, H.Sakamaki, O.Yamada, I.Jinnnai, K.Tsubaki, K.Takeyama, A.Hiraoka, S.Matsuda, M.Takahashi, C.Shimazaki, K.Adachi, S.Kageyama, T.Sakura, R.Ohno, for the Japan Adult Leukemia Study Group. /// Inter J Hematol 70:97-104,1999
Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991. /// M.Yoshida, K.Tsubaki, T.Kobayashi, M.Tanimoto, K.Kuriyama, H.Murakami, S.Minami, A.Hiraoka, I.Takahashi, T.Naoe, N.Asou, S.Kageyama, M.Tomonaga, H.Saito, R.Ohno, for the Japan Adult Leukemia Study Group. /// Inter J Hematol 70:261-267,1999
Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. /// Nakano Y. Kiyoi H. Miyawaki S. Asou N. Ohno R. Saito H. Naoe T. /// Br J Haematol 104: 659-664,1999
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. /// Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R. /// Blood 93: 3074-3080,1999
No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6- mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. /// S.Miyawaki, M.Tanimoto, T.Kobayashi, S.Minami, J.Tamura, E.Omoto, K.Kuriyama, K.Hatake, K.Saito, A.Kanamaru, H.Oh, S.Ohtake, N.Asou, H.Sakamaki, O.Yamada, I.Jinnnai, K.Tsubaki, K.Takeyama, A.Hiraoka, S.Matsuda, M.Takahashi, C.Shimazaki, K.Adachi, S.Kageyama, T.Sakura, R.Ohno, for the Japan Adult Leukemia Study Group. /// Inter J Hematol 70:97-104,1999
Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991. /// M.Yoshida, K.Tsubaki, T.Kobayashi, M.Tanimoto, K.Kuriyama, H.Murakami, S.Minami, A.Hiraoka, I.Takahashi, T.Naoe, N.Asou, S.Kageyama, M.Tomonaga, H.Saito, R.Ohno, for the Japan Adult Leukemia Study Group. /// Inter J Hematol 70:261-267,1999
Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. /// Nakano Y. Kiyoi H. Miyawaki S. Asou N. Ohno R. Saito H. Naoe T. /// Br J Haematol 104: 659-664,1999
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. /// Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R. /// Blood 93: 3074-3080,1999
Quantitative expression of erythropoietin receptor (EPO-R) on acute leiukaemia cells: relationships between the amount of EPO-R and CD phenothpes,in vitro proliferative response,the amount of other cytokine receptors and clinical prognosis. /// A.Takeshita, K.Takeshita, M.Higuchi, S.Miyawaki, Y.Takemoto, Y.Kishimoto, K.Saito, H.Taguchi, K.Kuriyama, Y.Kimura, N.Asou, M.Takahashi, T.Hotta, A.Kanamaru, R.Ueda, R.Ohno for the Japan Adult Leukemia Study Group. /// Br J Haematol 108:55-63,2000
Prognostic ｓignificance of the cell inhibitor p27 kip1 in acute myeloid leukemia. /// T.Yokozawa, M.Towatari, H.Iida, K.Takeyama, M.Tanimoto, H.Kiyoi, T.Motoji, N.sou, K.Saito, M.Takeuchi, Y.Kobayashi, S.Miyawaki, Y.Kodera, R.Ohno, H.Saito and T.Naoe for Japan Adult Leukemia Study Group. /// Leukemia 14:28-33,2000
Trisomy 10 in Acute Myeloid Leukemia: Three Additional Cases from the Database of the Japan Adult Leukemia Study Group (JALSG) AML-92 and AML-95. /// A.Suzuki, Y.Kimura, K.Ohyashiki, K.Kitano, S.Kageyama, M.Kasai, S.Miyawaki, and R.Ohno (Japan Adult Leukemia Study Group). /// Cancer Genet Cytogenet 120(2):141-143,2000
Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group(JALSG): Results of an interim analysis. /// T.Okamoto, A.Knamaru, C.Shimazaki, T.Motoji, Y.Takemoto, M.Takahashi, T.Fukushima, A.Takeshita, S.Kusumoto, Y.Kishimoto, S.Yorimitsu, K.Tsukuda, N.Uike, N.Arima, R.Ohno. /// Inter J Hematol 72(2):200-205,2000
Trisomy 11 acute myeloid leukemia: 5 additional cases from the Japan Adult Leukemia Study Group AML-92 and AML-95 databases. /// Suzuki A, Ohyashiki K, Kimura Y, Yamada H, Sano F, Miyawaki S, Kuriyama K, Ohno R; Japan Adult Leukemia Study Group. /// Int J Hematol 72:466-469,2000
How high can we increase complete remission rate in adult acute myeloid leukemia? /// Ohno R. /// Int J Hematol 72(3):272-279,2000
Allogeneic bone marrow transplantation improves the outcome of de novo AML with trilineage dysplasia(AML-TLD). /// Taguchi J, Miyazaki Y, Yoshida S, Fukushima T, Moriuchi Y, Jinnai I, Matsuo T, Kuriyama K, Tomonaga M. /// Leukemia 14(11):1861-1866,2000
Poor clinical significance of p53 gene polymorphism in acute myeloid leukemia. /// Nakano Y, Naoe T, Kiyoi H, Kunishima S, Minami S, Miyawaki S, Asou N, Kuriyama K, Saito H, Ohno R. /// Leuk Res 24:349-352,2000
Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia. /// Nakano Y, Naoe T, Kiyoi H, Kitamura K, Minami S, Miyawaki S, Asou N, Kuriyama K, Kusumoto S, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Saito H, Ohno R. /// Eur J Haematol 65: 23-31,2000
Prognostic ｓignificance of the cell inhibitor p27 kip1 in acute myeloid leukemia. /// T.Yokozawa, M.Towatari, H.Iida, K.Takeyama, M.Tanimoto, H.Kiyoi, T.Motoji, N.sou, K.Saito, M.Takeuchi, Y.Kobayashi, S.Miyawaki, Y.Kodera, R.Ohno, H.Saito and T.Naoe for Japan Adult Leukemia Study Group. /// Leukemia 14:28-33,2000
Trisomy 10 in Acute Myeloid Leukemia: Three Additional Cases from the Database of the Japan Adult Leukemia Study Group (JALSG) AML-92 and AML-95. /// A.Suzuki, Y.Kimura, K.Ohyashiki, K.Kitano, S.Kageyama, M.Kasai, S.Miyawaki, and R.Ohno (Japan Adult Leukemia Study Group). /// Cancer Genet Cytogenet 120(2):141-143,2000
Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group(JALSG): Results of an interim analysis. /// T.Okamoto, A.Knamaru, C.Shimazaki, T.Motoji, Y.Takemoto, M.Takahashi, T.Fukushima, A.Takeshita, S.Kusumoto, Y.Kishimoto, S.Yorimitsu, K.Tsukuda, N.Uike, N.Arima, R.Ohno. /// Inter J Hematol 72(2):200-205,2000
Trisomy 11 acute myeloid leukemia: 5 additional cases from the Japan Adult Leukemia Study Group AML-92 and AML-95 databases. /// Suzuki A, Ohyashiki K, Kimura Y, Yamada H, Sano F, Miyawaki S, Kuriyama K, Ohno R; Japan Adult Leukemia Study Group. /// Int J Hematol 72:466-469,2000
How high can we increase complete remission rate in adult acute myeloid leukemia? /// Ohno R. /// Int J Hematol 72(3):272-279,2000
Allogeneic bone marrow transplantation improves the outcome of de novo AML with trilineage dysplasia(AML-TLD). /// Taguchi J, Miyazaki Y, Yoshida S, Fukushima T, Moriuchi Y, Jinnai I, Matsuo T, Kuriyama K, Tomonaga M. /// Leukemia 14(11):1861-1866,2000
Poor clinical significance of p53 gene polymorphism in acute myeloid leukemia. /// Nakano Y, Naoe T, Kiyoi H, Kunishima S, Minami S, Miyawaki S, Asou N, Kuriyama K, Saito H, Ohno R. /// Leuk Res 24:349-352,2000
Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia. /// Nakano Y, Naoe T, Kiyoi H, Kitamura K, Minami S, Miyawaki S, Asou N, Kuriyama K, Kusumoto S, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Saito H, Ohno R. /// Eur J Haematol 65: 23-31,2000
